Transaction #9891 · Form 4 · 0001782135-25-000013
GILEAD SCIENCES, INC. · Exercise / conversion · Common Stock
GILEAD SCIENCES, INC. · Transacted November 17, 2025 · Filed November 18, 2025
What does this filing report?
An SEC Form 4 filing for GILEAD SCIENCES, INC. records an exercise / conversion involving Common Stock on November 17, 2025. The reported quantity was 25,000. The filing date is November 18, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- GILEAD SCIENCES, INC.
- Company CIK
- 0000882095
- Security type
- Non-derivative
- Acquisition type
- Exercise / conversion · Code M
- Quantity acquired
- 25,000
- Reported price
- 66.64
- Reference value
- 1,666,000
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 135,193
- Ownership description
- Not reported
- SEC acceptance time
- Nov 18, 2025, 6:51 PM EST
- 10b5-1 indication
- Indicated in filing
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Mercier Johanna ↗
Chief Commercial Officer
CIK 0001782135
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.
- F2
- Sales prices for the transactions reported here range from $125.23 to $126.20. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- F3
- Sales prices for the transactions reported here range from $126.23 to $126.39. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- F4
- The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.